BlackRock, Inc. 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-26 5:25 pm Sale | 2023-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 8,546,557 6.800% | -119,145 (-1.37%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 8,665,702 7.000% | 994,300 (+12.96%) | Filing |
| 2022-02-02 7:11 pm Sale | 2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 7,671,402 6.400% | -1,052,318 (-12.06%) | Filing |
| 2021-01-28 5:56 pm Purchase | 2020-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 8,723,720 7.500% | 690,464 (+8.60%) | Filing |
| 2020-02-05 11:26 am Purchase | 2019-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 8,033,256 7.200% | 1,887,451 (+30.71%) | Filing |